ARGENX SE-ADR (NASDAQ:ARGX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Tuesday. The brokerage currently has a $26.00 price objective on the stock. Zacks Investment Research‘s target price would suggest a potential upside of 13.09% from the company’s previous close.

According to Zacks, “argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands. “

Separately, Cowen and Company reissued a “buy” rating on shares of ARGENX SE-ADR in a report on Thursday, August 24th.

ARGENX SE-ADR (ARGX) traded down 1.23% during mid-day trading on Tuesday, hitting $22.99. The stock had a trading volume of 10,255 shares. The firm’s market capitalization is $617.76 million. The stock’s 50 day moving average price is $23.01 and its 200 day moving average price is $21.44. ARGENX SE-ADR has a one year low of $17.33 and a one year high of $27.25.

ILLEGAL ACTIVITY NOTICE: “ARGENX SE-ADR (ARGX) Upgraded to Buy at Zacks Investment Research” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.americanbankingnews.com/2017/10/24/argenx-se-adr-argx-upgraded-to-buy-at-zacks-investment-research.html.

Institutional investors have recently bought and sold shares of the business. Nicholas Investment Partners LP bought a new position in ARGENX SE-ADR during the 2nd quarter worth $236,000. DAFNA Capital Management LLC bought a new position in ARGENX SE-ADR during the 2nd quarter worth $848,000. Tekla Capital Management LLC bought a new position in ARGENX SE-ADR during the 2nd quarter worth $1,591,000. AWM Investment Company Inc. bought a new position in ARGENX SE-ADR during the 2nd quarter worth $2,121,000. Finally, Jennison Associates LLC bought a new position in ARGENX SE-ADR during the 2nd quarter worth $2,657,000. Hedge funds and other institutional investors own 22.74% of the company’s stock.

About ARGENX SE-ADR

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Get a free copy of the Zacks research report on ARGENX SE-ADR (ARGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ARGENX SE-ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARGENX SE-ADR and related companies with MarketBeat.com's FREE daily email newsletter.